Your browser doesn't support javascript.
loading
Clinical Impact of Standardized TAVR Technique and Care Pathway: Insights From the Optimize PRO Study.
Grubb, Kendra J; Gada, Hemal; Mittal, Suneet; Nazif, Tamim; Rodés-Cabau, Josep; Fraser, Douglas G W; Lin, Lang; Rovin, Joshua D; Khalil, Ramzi; Sultan, Ibrahim; Gardner, Blake; Lorenz, David; Chetcuti, Stanley J; Patel, Nainesh C; Harvey, James E; Mahoney, Paul; Schwartz, Brian; Jafar, Zubair; Wang, John; Potluri, Srinivasa; Vora, Amit N; Sanchez, Carlos; Corrigan, Amy; Li, Shuzhen; Yakubov, Steven J.
Afiliação
  • Grubb KJ; Division of Cardiothoracic Surgery, Emory University, Atlanta, Georgia, USA. Electronic address: kjgrubb@emory.edu.
  • Gada H; Department of Interventional Cardiology, University of Pittsburgh Medical Center Pinnacle, Wormleysburg, Pennsylvania, USA; Center for Heart Valve Disease, Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
  • Mittal S; Division of Cardiology and the Snyder Center for Comprehensive Atrial Fibrillation at Valley Health System, Ridgewood, New Jersey, USA.
  • Nazif T; NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, USA.
  • Rodés-Cabau J; Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada; Hospital Clínic de Barcelona, Barcelona, Spain.
  • Fraser DGW; Cardiology Department, Manchester Heart Centre, Central Manchester University Hospitals, Manchester Royal Infirmary, Manchester, United Kingdom.
  • Lin L; Department of Interventional Cardiology, Morton Plant Hospital, Clearwater, Florida, USA; Department of Cardiovascular Surgery, Morton Plant Hospital, Clearwater, Florida, USA.
  • Rovin JD; Department of Interventional Cardiology, Morton Plant Hospital, Clearwater, Florida, USA; Department of Cardiovascular Surgery, Morton Plant Hospital, Clearwater, Florida, USA.
  • Khalil R; Department of Cardiology, Allegheny General Hospital, Pittsburgh, Pennsylvania, USA.
  • Sultan I; Department of Interventional Cardiology, University of Pittsburgh Medical Center Pinnacle, Wormleysburg, Pennsylvania, USA; Center for Heart Valve Disease, Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
  • Gardner B; Saint George Regional Hospital, St. George, Utah, USA.
  • Lorenz D; Saint Vincent's Medical Center, Bridgeport, Connecticut, USA.
  • Chetcuti SJ; Department of Interventional Cardiology, University of Michigan Hospitals, Ann Arbor, Michigan, USA; Department of Cardiovascular Surgery, University of Michigan Hospitals, Ann Arbor, Michigan, USA.
  • Patel NC; Division of Cardiology, Lehigh Valley Health Network/University of South Florida College of Medicine, Allentown, Pennsylvania, USA.
  • Harvey JE; Department of Cardiovascular Diseases, York Hospital-Wellspan Health System, York, Pennsylvania, USA.
  • Mahoney P; Structural Heart Center, Sentara Heart Hospital, Norfolk, Virginia, USA.
  • Schwartz B; Department of Cardiology, Kettering Medical Center, Dayton, Ohio, USA.
  • Jafar Z; Department of Cardiology, Vassar Brothers Medical Center, Poughkeepsie, New York, USA.
  • Wang J; Section of Interventional Cardiology, MedStar Union Memorial Hospital, Baltimore, Maryland, USA.
  • Potluri S; Department of Interventional Cardiology, Baylor Scott and White The Heart Hospital, Plano, Texas, USA.
  • Vora AN; Department of Interventional Cardiology, University of Pittsburgh Medical Center Pinnacle, Wormleysburg, Pennsylvania, USA; Center for Heart Valve Disease, Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
  • Sanchez C; Department of Interventional Cardiology, Riverside Methodist-OhioHealth, Columbus, Ohio, USA.
  • Corrigan A; Department of Clinical Research, Medtronic, Minneapolis, Minnesota, USA.
  • Li S; Department of Structural Heart and Aortic Clinical Research and Medical Science, Medtronic, Minneapolis, Minnesota, USA.
  • Yakubov SJ; Department of Interventional Cardiology, Riverside Methodist-OhioHealth, Columbus, Ohio, USA.
JACC Cardiovasc Interv ; 16(5): 558-570, 2023 03 13.
Article em En | MEDLINE | ID: mdl-36922042
ABSTRACT

BACKGROUND:

Procedural success and clinical outcomes after transcatheter aortic valve replacement (TAVR) have improved, but residual aortic regurgitation (AR) and new permanent pacemaker implantation (PPI) rates remain variable because of a lack of uniform periprocedural management and implantation.

OBJECTIVES:

The Optimize PRO study evaluates valve performance and procedural outcomes using an "optimized" TAVR care pathway and the cusp overlap technique (COT) in patients receiving the Evolut PRO/PRO+ (Medtronic) self-expanding valves.

METHODS:

Optimize PRO, a nonrandomized, prospective, postmarket study conducted in the United States, Canada, Europe, Middle East, and Australia, is enrolling patients with severe symptomatic aortic stenosis and no pre-existing pacemaker. Sites follow a standardized TAVR care pathway, including early discharge and a conduction disturbance management algorithm, and transfemoral deployment using the COT.

RESULTS:

A total of 400 attempted implants from the United States and Canada comprised the main cohort of this second interim analysis. The mean age was 78.7 ± 6.6 years, and the mean Society of Thoracic Surgeons predictive risk of mortality was 3.0 ± 2.4. The median length of stay was 1 day. There were no instances of moderate or severe AR at discharge. At 30 days, all-cause mortality or stroke was 3.8%, all-cause mortality was 0.8%, disabling stroke was 0.7%, hospital readmission was 10.1%, and cardiovascular rehospitalization was 6.1%. The new PPI rate was 9.8%, 5.8% with 4-step COT compliance. In the multivariable model, right bundle branch block and the depth of the implant increased the risk of PPI, whereas using the 4-step COT lowered 30-day PPI.

CONCLUSIONS:

The use of the TAVR care pathway and COT resulted in favorable clinical outcomes with no moderate or severe AR and low PPI rates at 30 days while facilitating early discharge and reproducible outcomes across various sites and operators. (Optimize PRO; NCT04091048).
Assuntos
Palavras-chave

Texto completo: 1 Eixos temáticos: Pesquisa_clinica Base de dados: MEDLINE Assunto principal: Insuficiência da Valva Aórtica / Estenose da Valva Aórtica / Próteses Valvulares Cardíacas / Acidente Vascular Cerebral / Substituição da Valva Aórtica Transcateter Tipo de estudo: Etiology_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Aged80 / Humans País como assunto: America do norte Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Eixos temáticos: Pesquisa_clinica Base de dados: MEDLINE Assunto principal: Insuficiência da Valva Aórtica / Estenose da Valva Aórtica / Próteses Valvulares Cardíacas / Acidente Vascular Cerebral / Substituição da Valva Aórtica Transcateter Tipo de estudo: Etiology_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Aged80 / Humans País como assunto: America do norte Idioma: En Ano de publicação: 2023 Tipo de documento: Article